Table 4.
Summary of Pharmacological Augmentation Recommendations by Guideline
| APA | BAP | CANMAT | CPGS | ICSI | NICE | MPG | RANZCP | TMAP | WFSBP | |
|---|---|---|---|---|---|---|---|---|---|---|
| AAPs1 | 2nd | 1st | 1st | 1st | ✔ | 1st | 1st | 1st | 2nd | 1st |
| Lithium | 2nd | 1st | 2nd | 1st | ✔ | ✔ | 1st | 1st | ✔ | 1st |
| Other mood stabilisers | ✔ | 2nd 1 | ✘ | ✘ | – | ✘ | 2nd 1 | – | ✔a | – |
| Thyroid hormones | 2nd | 2nd | 2nd | ✘ | ✔ | ✘ | 2nd | 1st | 1st | 2nd |
| Stimulants | ✔ | ✔ | 2ndb | – | ✔ | ✘ | ✔ | ✘ | – | – |
| Bupropion | ✔ | ✔ | 2nd | ✘ | ✔ | ✘ | 1st | ✘ | 1st | ✘ |
| Buspirone | ✔ | ✔ | ✘ | ✘ | ✔ | ✘ | 2nd | ✘ | 1st | ✘ |
| Ketamine | – | ✘ | ✔ | – | ✔ | – | 2nd | ✘ | – | ✘ |
Abbreviations: 1st, first-line recommendation or equivalent; 2nd, second-line recommendation or equivalent; ✔, other recommendation/level not specified, ✘, not recommended, —, treatment not discussed by guideline; AAPs, atypical antipsychotics; APA, American Psychiatric Association; BAP, British Association of Psychopharmacology; CANMAT, Canadian Network for Mood and Anxiety Disorders; CPG-S, Clinical Practice Guidelines in the Spanish NHS; ICSI, Institute for Clinical Systems Improvement; NICE, National Institute for Health and Care Excellence; RANZCP, Royal Australian and New Zealand College of Psychiatrists; MPG, Maudsley Prescribing Guidelines; TMAP; Texas Medication Algorithm Project; WFSBP, World Federation of Societies of Biological Psychiatry.
aSpecific combination/medication subtype recommendation.
bAt least 1 of this class of drug recommended at indicated level.